MEASUREMENT OF CLINICAL-CHANGE IN PROGRESSIVE SYSTEMIC-SCLEROSIS - 1-YEAR DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF N-ACETYLCYSTEINE
MEASUREMENT OF CLINICAL-CHANGE IN PROGRESSIVE SYSTEMIC-SCLEROSIS - 1-YEAR DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF N-ACETYLCYSTEINE
复制标题
DOI：
10.1136/ard.38.4.356
复制
发表时间：
1979-01-01
影响因子：
27.4
通讯作者：
PAULUS, HE
中科院分区：
文献类型：
--
作者：
FURST, DE;CLEMENTS, PJ;PAULUS, HE
N-acetylcysteine [NAC] was used as a therapeutic agent in a 1 yr, parallel, double-blind, placebo-controlled, prospective study of 22 patients with progressive systemic sclerosis (PSS). Patients were closely followed-up and were extensively evaluated at baseline, 6 and 12 mo. Most parameters remained unchanged during 1 yr of study in both the NAC and placebo groups, which showed the need for prolonged studies of drugs in PSS if definitive results are to be obtained. Over the year the diffusing capacity decreased in both groups and several other parameters measured both increased and decreased. Several simple measures of function and skin distensibility were tested and 2 (oral aperature and handspread) were reproducible and sensitive enough to measure moderate changes of disease activity. They may be useful in future trials of drug effect in PSS.
